Enspryng (tirzepatide) is a once‑weekly injectable medication used to improve glycemic control in adults with type 2 diabetes, often as an add‑on to diet and exercise or to another antidiabetic therapy. It is a dual GIP/GLP‑1 receptor agonist that lowers blood glucose, reduces body weight, and can lower systolic blood pressure.
Key points
| What |
Detail |
| Approval status (EMA) |
Enspryng received a positive opinion and was approved by the European Medicines Agency in April 2024 for use in type 2 diabetes. |
| Indication |
Adults with type 2 diabetes, either as monotherapy or add‑on to diet/exercise or another antidiabetic drug. |
| Dosage |
Starting dose 5 mg once weekly. Can be titrated to 10 mg, then 15 mg, and up to 20 mg depending on tolerance and glycemic response. |
| Benefits |
• HbA1c reduction up to ~1.8 % in clinical trials.
• Average weight loss ≈ 6–10 kg (depending on dose).
• Improved systolic blood pressure (~2–5 mm Hg). |
| Common side‑effects |
Nausea, vomiting, diarrhea, decreased appetite, constipation, injection‑site reactions, and, rarely, pancreatitis or gallbladder disease. |
| Contraindications |
Known hypersensitivity to tirzepatide or any component; active or history of medullary thyroid carcinoma or MEN 2A; pregnancy or breastfeeding (insufficient data). |
| Monitoring |
• HbA1c every 3–6 months.
• Weight and blood pressure.
• Watch for signs of pancreatitis or gallbladder disease.
• If using other antidiabetics, monitor for hypoglycaemia. |
| Drug interactions |
Mainly pharmacodynamic; watch for other agents that lower glucose (e.g., insulin, sulfonylureas). No major pharmacokinetic interactions known. |
| Patient counseling |
• Inject once weekly, same time each week.
• Rotate injection sites (abdomen, thigh, upper arm).
• Store refrigerated (2–8 °C) and keep at room temp (≤ 30 °C) for 30 days before use.
• Report persistent nausea or signs of pancreatitis (abdominal pain, vomiting). |
Quick FAQ
Q: Is Enspryng approved for weight loss only?
A: No, it’s approved for type 2 diabetes. Weight loss is a benefit, but it’s not a dedicated weight‑loss drug.
Q: Can it be used in people with type 1 diabetes?
A: No, it’s not approved for type 1 diabetes. Use of GLP‑1 agonists in type 1 is off‑label and not supported by EMA approval.
Q: Does it increase the risk of thyroid cancer?
A: In animal studies, high doses caused thyroid C‑cell hyperplasia, but the clinical significance in humans is still under investigation. No definitive evidence of increased risk in human trials so far.
Q: How does Enspryng compare with other GLP‑1 agonists?
A: Tirzepatide (Enspryng) typically shows greater HbA1c and weight reduction than other GLP‑1 agents (e.g., semaglutide). However, individual response and tolerability vary.
Bottom line
Enspryng (tirzepatide) is a novel, dual‑agonist injectable therapy that has been approved by the EMA for adults with type 2 diabetes, offering strong glycaemic control and weight loss. As always, therapy should be tailored to the individual, with ongoing monitoring for efficacy and side‑effects. If you have more specific questions (e.g., dosing in renal impairment, pregnancy safety, or insurance coverage), feel free to ask!